Expertise in
24
conditions

Dr. Sashi K. Makam

Internal Medicine
Office
1460 State Route 17M, 
Chester, NY 
Offers Telehealth
Expertise in
24
conditions
Office
1460 State Route 17M, 
Chester, NY 

Overview

Sashi Makam is a primary care provider, practicing in Internal Medicine in Chester, New York.

Dr. Makam is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Hypothyroidism, Obesity in Children, High Cholesterol, and Familial Hypertriglyceridemia.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 14 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in NY

Hospital Affiliations

Montefiore St Luke's Cornwall
Vassar Brothers Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
Nippon Life
  • INSURANCE PLAN
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

Office
1460 State Route 17M, Chester, NY 10918

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Mixed Dyslipidemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: April 14, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2025
Intervention Type: Drug
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Other
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening BLUE-C
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 01, 2023
Intervention Type: Procedure, Diagnostic test
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

1 Total Publications

Varicella-Zoster Virus Reactivation Following Acute Babesiosis in an Immunocompromised Patient: A Case Report.
Varicella-Zoster Virus Reactivation Following Acute Babesiosis in an Immunocompromised Patient: A Case Report.
Journal: Cureus
Published: May 05, 2026
Similar Doctors
Expertise in
39
conditions
Dr. Mark G. Lebwohl
Internal Medicine
Expertise in
39
conditions
Dr. Mark G. Lebwohl
Internal Medicine
Before you request

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (42.1 miles away)
212-241-9728
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Lebwohl is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Lebwohl is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Plaque Psoriasis, Psoriasis, Pustular Psoriasis, and Generalized Pustular Psoriasis (GPP). Dr. Lebwohl is currently accepting new patients.

Expertise in
56
conditions
Dr. Wilbert S. Aronow
Internal Medicine
Expertise in
56
conditions
Dr. Wilbert S. Aronow
Internal Medicine

Office

19 Bradhurst Ave Ste 1700GG, 
Hawthorne, NY 
 (29.6 miles away)
914-493-5883
Languages Spoken:
English
See accepted insurances

Wilbert Aronow is a primary care provider, practicing in Internal Medicine in Hawthorne, New York. Dr. Aronow is highly rated in 56 conditions, according to our data. His clinical expertise encompasses Heart Failure, Heart Attack, Hypertension, Percutaneous Coronary Intervention (PCI), and Aortic Valve Replacement.

Expertise in
17
conditions
Dr. Gerald B. Appel
Internal Medicine
Expertise in
17
conditions
Dr. Gerald B. Appel
Internal Medicine

ColumbiaDoctors - Tarrytown

155 White Plains Rd, 
Tarrytown, NY 
 (28.9 miles away)
845-751-3159
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gerald Appel is a primary care provider, practicing in Internal Medicine in Tarrytown, New York. Dr. Appel is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Glomerulonephritis, IgA Nephropathy, Nephrotic Syndrome, Kidney Transplant, and Nephrectomy.

Frequently Asked Questions about Dr. Sashi K. Makam

How do I make an appointment with Dr. Sashi K. Makam?

You can book an appointment with Dr. Sashi K. Makam by calling their office at 845-469-4211. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sashi K. Makam a top-rated expert for Hypothyroidism?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sashi K. Makam is classified as an Distinguished expert for Hypothyroidism, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sashi K. Makam specialize in?

While Dr. Sashi K. Makam is a Internal Medicine, they have specific expertise in Hypothyroidism, Obesity in Children, and High Cholesterol. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Sashi K. Makam participate in research or clinical trials?

Yes. Dr. Sashi K. Makam has published 1 articles and abstracts on conditions like Hypothyroidism. You can view a list of Dr. Sashi K. Makam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sashi K. Makam accept my insurance?

Dr. Sashi K. Makam accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 845-469-4211 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Makam's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 190 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile